Drug Profile
Nadunolimab - Cantargia
Alternative Names: CAN-04; Nidanilimab - CantargiaLatest Information Update: 12 Apr 2024
Price :
$50
*
At a glance
- Originator Lund University
- Developer Cantargia; Pancreatic Cancer Action Network
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Interleukin-1 receptor accessory protein inhibitors; Natural killer cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Pancreatic cancer
- Phase II Non-small cell lung cancer
- Phase I/II Solid tumours; Triple negative breast cancer
Most Recent Events
- 08 Apr 2024 Pharmacodynamics data from preclinical studies in Pancreatic cancer released by Cantargia
- 08 Apr 2024 Cantargia plans a phase IIb trial for Pancreatic cancer (First line therapy) in summer 2024
- 27 Mar 2024 Cantargia plans a phase Ib/IIa trial for acute myeloid leukemia or myelodysplastic syndrome (Combination therapy) in USA